Kura to show longer follow-up on darlifarnib-cabozantinib in kidney cancer
The July 24 presentation extends Phase 1a data already showing a 44% response rate in pretreated patients, this time in cabozantinib-naive advanced clear cell RCC.
Executive Summary
- Kura Oncology will present longer follow-up on its darlifarnib-cabozantinib combination in kidney cancer, extending a Phase 1a dataset that already showed activity in a related, heavily pretreated cohort.
- The update matters less as a standalone data point and more as another checkpoint toward selecting a Phase 3 dose from an ongoing randomized comparison, ahead of a registrational study Kura has said it plans for 2028.
- No other clinical-stage program pairs a farnesyl transferase inhibitor with a VEGFR-targeted therapy in this kidney cancer population, leaving Kura's combination without a direct mechanistic comparator in the field.
- The combination's earlier disclosed response and disease-control rates set the bar this update needs to sustain as more patients accumulate longer exposure to the regimen.
The presentation
Kura Oncology said it will feature the FIT-001 update in an oral session at the 2026 Kidney Cancer Research Summit in Boston on July 24, covering long-term follow-up in heavily pretreated, cabozantinib-naive patients with refractory renal cell carcinoma. The trial, registered as NCT06026410 and known by the acronym FIT-001, is a Phase 1 study of KO-2806 (darlifarnib) monotherapy and combination regimens across advanced tumors, recruiting toward an anticipated enrollment of 300 patients across the United States, Italy, France, Spain and Germany. Mollie Leoni, Kura's Chief Medical Officer, said the update will further inform the combination's potential in advanced clear cell RCC and build on evidence for darlifarnib's mechanism across VEGF-TKI, KRAS and PI3K-alpha combinations. Kura+1Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s ...Jul 14, 2026KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The prior data point
Kura has already disclosed activity from FIT-001 in a related but distinct population. In 16 cabozantinib-pretreated ccRCC patients, the combination produced a 44% objective response rate and a 94% disease control rate, with tumor shrinkage in 75% of patients and treatment durations spanning 8 to 56 weeks, six of whom remained on therapy at the data cutoff. Safety in that cohort was described as manageable and consistent with the drugs' known profiles. The July 24 presentation extends this evidence base to the cabozantinib-naive setting, where the trial's registered primary endpoints are dose-limiting toxicity rates and descriptive adverse-event statistics rather than a formal efficacy comparison. Kura+1Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s ...Jul 14, 2026KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410
Trial design and status
FIT-001 has been recruiting since October 2023, with a primary completion date of January 2027 and full completion targeted for April 2027. Enrollment moved from 270 to 300 patients in a registry update dated January 2, 2026, an increase within the routine range for an early-phase trial and not flagged by operational risk thresholds. Kura is now enrolling patients in a randomized Phase 1b dose-optimization portion comparing darlifarnib plus cabozantinib against cabozantinib alone in cabozantinib-naive, refractory advanced ccRCC, designed to select a recommended Phase 3 dose ahead of a registrational study the company has said it plans to start in 2028. NCT06026410+1KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsNCT06026410Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s ...Jul 14, 2026
Competitive landscape
No competing clinical-stage program combines a farnesyl transferase inhibitor with a VEGFR-targeted therapy in this cabozantinib-naive ccRCC population; the nearest comparators identified in the broader field, including PD-1, KRAS G12C, and HIF-2-alpha directed programs in Phase 3 testing for renal and other tumors, share the indication or modality but not the target or mechanism class. That leaves darlifarnib plus cabozantinib without a validated direct precedent in this pairing, with the combination's own prior cabozantinib-pretreated results standing as the closest available benchmark for what durable activity in this drug class could look like.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.